/Zhonghong Medical: Third Quarter Report of 2025

NEWS

Zhonghong Medical: Third Quarter Report of 2025

Shenzhen Stock Exchange

2025/10/29

Zhonghong Pulin Medical Products Co., Ltd. 2025 Third Quarter Report

Securities code: 300981 Securities abbreviation: Zhonghong Medical Announcement number: 2025-096

Zhonghong Pulin Medical Products Co., Ltd.

2025 Third Quarter Report

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions. Important content reminder:

The board of directors, directors and senior managers guarantee that the quarterly report is true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report.
Whether the third quarter financial accounting report has been audited

□Yes No

Zhonghong Pulin Medical Products Co., Ltd. 2025 Third Quarter Report

1. Main financial data

(1) Main accounting data and financial indicators

Whether the company needs to retroactively adjust or restate previous years’ accounting data

Yes □No

Reasons for retrospective adjustments or restatements

other reasons

Year-to-date reporting period

The end of the reporting period is the same as the same period last year. The year-end report is the same period last year.

Increase/decrease in the same period of the previous year during this reporting period End of period

increase or decrease

Before adjustment After adjustment After adjustment Before adjustment After adjustment Adjusted operating income 626,124,0 689,837,8 689,837,8 1,863,658 1,838,289 1,838,289

-9.24% 1.38% (yuan) 15.80 65.07 65.07,896.34,686.09,686.09

Belong to the top

Municipal company shares 18,502,43 18,502,43 51,032,30 51,032,30

12,953,08 -170.01% 7,210,152 -114.13% Dong’s net profit 6.81 6.81 5.48 5.48

6.92 .72

Run (yuan)

Belong to the top

Municipal company shares

Deductions for East - - - - -

4,088,449 4,088,449

Non-recurring 24,170,43 -691.19% 37,344,92 183,696.4 183,696.4 20,229.69

.31 .31

Net profit and loss 1.92 2.50 4 4 % profit

(yuan)

Business activities

Cash generated 13,138,48 13,138,48

- - - 90,666,37 -790.08% Net gold flow 4.56 4.56

5.21

Amount (yuan)

basic share

Income (yuan/-0.0303 0.0476 0.0433 -169.98% -0.0169 0.1312 0.1193 -114.17% shares)

diluted per share

Income (yuan/-0.0303 0.0476 0.0433 -169.98% -0.0169 0.1312 0.1193 -114.17% shares)

weighted average

Net assets received -0.24% 0.33% 0.33% -0.57% -0.13% 0.89% 0.89% -1.02% profit margin

The end of this reporting period is higher than the end of the previous year.

Increase or decrease at the end of this reporting period

Before adjustment After adjustment After adjustment

total assets

7,652,079,297.02 7,230,360,796.53 7,230,360,796.53 5.83% (yuan)

Belong to the top

Municipal company shares

All 5,368,713,903.59 5,474,102,359.07 5,474,102,359.07 -1.93% equity interests

(yuan)

(2) Non-recurring profit and loss items and amounts

Applicable □Not applicable

Unit: Yuan

Zhonghong Pulin Medical Products Co., Ltd. 2025 Third Quarter Report

Item Amount for this reporting period Amount from the beginning of the reporting period to the end of the reporting period Explanation of gains and losses from disposal of non-current assets (including

Including provisions for asset impairment losses -59,359.12 -868,867.52

pin part)

Government subsidies included in current profits and losses

(Close to the normal business operations of the company

Relevant, in line with national policies and regulations,

2,135,133.23 5,490,256.20

enjoy according to determined standards, and benefit the public

government that has a lasting impact on the company's profits and losses

Except for subsidies)

Except related to the company's normal business operations

In addition to effective hedging business, non-

Financial enterprises hold financial assets and gold

12,534,978.43 33,480,540.87

Changes in fair value of financial liabilities

Profit and loss and disposal of financial assets and funds

Profit and loss arising from financial liabilities

Other businesses other than the above

310,977.33 1,340,153.95

external income and expenses

Less: Income tax impact 1,317,246.83 6,904,907.20

Amount affected by minority shareholders’ equity

2,387,138.04 2,402,406.52

(after tax)

Total 11,217,345.00 30,134,769.78 --Details of other profit and loss items that meet the definition of non-recurring profits and losses:

□Applicable Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

□Applicable Not applicable

The company does not define the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items.

(3) Changes in major accounting data and financial indicators and their reasons

Applicable □Not applicable

Balance sheet items

Unit: Yuan

Item Ending balance Beginning balance Change range Description Monetary funds 802,308,968.19 597,585,652.51 34.26% Mainly due to increase in financing Notes receivable 974,887.19 2,789,352.84 -65.05% Mainly due to changes in settlement methods for receivables financing 2,276,060.17 1,024,680.31 122.12% Mainly due to prepayments due to changes in settlement methods 92,556,323.80 48,118,631.65 92.35% Mainly due to the increase in prepayments due within one year

157,464,000.00 -100.00% Mainly due to the decrease in assets of long-term financial products due within one year

Construction in progress 152,661,985.87 84,090,530.68 81.54% Mainly due to the renovation of fixed assets Other non-current assets 195,710,428.82 108,272,718.50 80.76% Mainly due to the increase in prepaid land payment Short-term borrowings 842,421,511.72 391,527,277.31 115.16% Mainly due to the increase in financing

Zhonghong Pulin Medical Products Co., Ltd. 2025 Third Quarter Report

Trading financial liabilities 7,688,017.08 16,082,792.40 -52.20% Mainly due to the decrease in the equity transfer consideration payable Notes payable 160,542,625.01 233,884,319.01 -31.36% Mainly due to the change in settlement method

Taxes payable 6,159,788.11 13,070,467.19 -52.87% Mainly due to the decrease in corporate income tax Other payables 13,827,372.70 28,093,052.42 -50.78% Mainly due to the decrease in equity acquisition payables Other current liabilities 2,588,264.54 8,880,799.80 -70.86% Mainly due to the expected decrease in sales rebates and long-term borrowings 561,349,847.14 330,213,742.94 70.00% Mainly due to the increase in financing

Lease liabilities 16,245,097.12 8,573,902.35 89.47% Mainly due to newly leased right-of-use assets

Income statement items

Unit: Yuan

Project January-September 2025 January-September 2024 Change Range Description

Taxes and surcharges 18,636,121.65 13,940,483.58 33.68% Mainly due to the increase in urban maintenance and construction taxes Other income 8,851,857.94 15,854,350.20 -44.17% Mainly due to investment income due to the decrease in government subsidies (losses are marked with "-"

8,761,768.44 13,338,656.88 -34.31% Mainly due to the decrease in financial management income)

Credit impairment losses (losses begin with “-

-2,511,375.33 -1,707,513.10 -47.08% Mainly due to the increase in bad debt losses on accounts receivable (please enter the number ")

Asset impairment losses (losses are represented by “-

-25,099,406.45 -42,547,150.18 41.01% Mainly due to the decrease in losses from inventory depreciation (please enter the number ")

Gains on asset disposals (losses are represented by “-

-792,071.20 -2,322.57 -34,003.22% Mainly due to the increase in losses from disposal of fixed assets (please fill in the number ")

Non-operating income 2,083,617.67 171,870.99 1,112.31% Mainly due to the increase in settlement accounts payable 392,118.66 7,356,176.66 -94.67% Mainly due to the decrease in income tax for the current period

Cash flow statement items

Unit: Yuan

Project January-September 2025 January-September 2024 Change Range Description

Cash flow generated from operating activities is mainly due to the increase in cash paid for purchasing goods and receiving services.

-90,666,375.21 13,138,484.56 -790.08%

Net amount due to

cash flow from investing activities

-100,101,177.87 477,458,315.08 -120.97% Mainly due to the increase in cash paid for investments, net amount

cash flow from financing activities

387,456,527.41 145,056,064.44 167.11% Mainly due to the increase in cash received from borrowings, net amount

2. Shareholder information

(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders

Unit: Share Total number of common shareholders at the end of the reporting period 22,418 Total number of preference shareholders with restored voting rights at the end of the reporting period (if any) 0 Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)

Holding of sales restrictions Pledge, mark or freeze Name of shareholder Nature of shareholder Shareholding ratio Number of shares held

Number of shares of the piece Share status Quantity Zhonghong Pulin Group

State-owned legal person 45.01% 193,050,000 0 Not applicable 0 Limited company

Xiamen International Trade Holdings

State-owned legal person 15.15% 64,993,500 0 Not applicable 0 Group Co., Ltd.

Mulberry Army Domestic natural person 11.14% 47,773,440 35,830,080 Not applicable 0

Zhonghong Pulin Medical Products Co., Ltd. 2025 Third Quarter Report

Shanghai Luanwei Trading Domestic Non-State-owned Law

0.79% 3,378,779 0 Not applicable 0 Co., Ltd. Person

Hong Kong Securities Clearing Company

Overseas legal person 0.38% 1,624,372 0 Not applicable 0 Limited company

Song Jun Overseas natural person 0.19% 800,000 0 Not applicable 0 China Merchants Bank shares

Co., Ltd.-Yong

Win China Securities Comprehensive Medical Consultation

Others 0.19% 794,656 0 Not applicable 0 Therapeutic device trading type

open index certificate

securities investment funds

Jiang Guoping Domestic natural person 0.14% 600,000 0 Not applicable 0Zhang Zhoutong Domestic natural person 0.14% 600,000 0 Not applicable 0Liu Langlang Domestic natural person 0.13% 562,340 0 Not applicable 0Shareholdings of the top 10 shareholders without selling restrictions (excluding shares lent through refinancing and executive locked shares)

Type and quantity of shares

Name of shareholder Number of shares without selling restrictions held

Type of shares Quantity Zhonghong Pulin Group Co., Ltd. 193,050,000 RMB ordinary shares 193,050,000 Xiamen International Trade Holding Group Co., Ltd. 64,993,500 RMB ordinary shares 64,993,500 Sang Shujun 11,943,360 RMB ordinary shares 11,943,360 Shanghai Luanwei Trading Co., Ltd. 3,378,779 RMB ordinary shares 3,378,779 Hong Kong Securities Clearing Company Limited 1,624,372 RMB ordinary shares 1,624,372 Song Jun 800,000 RMB ordinary shares 800,000 China Merchants Bank Co., Ltd.-Yongyingzhong

Securities Comprehensive Medical Device Trading Open-End Index 794,656 RMB ordinary shares 794,656 Securities investment funds

Jiang Guoping 600,000 RMB ordinary shares 600,000 Zhang Zhoutong 600,000 RMB ordinary shares 600,000 Liu Langlang 562,340 RMB ordinary shares 562,340

Xiamen International Trade Holding Group Co., Ltd. and Zhonghong Purin Group Co., Ltd. (hereinafter referred to as "Zhonghong Purin Group") are related parties. Xiamen International Trade Holdings holds 50.50% of the equity of Zhonghong Purin Group.
Sang Shujun and Zhonghong Pulin Group are related parties, and Sang Shujun, through the companies it controls, north of the above-mentioned shareholders’ related relationships or concerted actions. Jingshujun Holding Group Co., Ltd. holds 44.62% of the equity of Zhonghong Pulin Group.
Shanghai Luanwei Trading Co., Ltd. holds 4.88% of the equity of Zhonghong Pulin Group.
In addition, the company does not know whether there is an associated relationship or concerted action relationship between the other top 10 shareholders of unrestricted tradable shares, as well as the top 10 shareholders of unrestricted tradable shares and the top 10 shareholders.

Liu Langlang holds a total of 562,340 shares of the company, including an explanation of the top 10 shareholders who participate in margin trading and securities lending business through ordinary securities accounts (such as

There are 0 company shares, and 562,340 company shares are held through credit transaction guaranteed securities accounts)

shares.

Note: The company’s special repurchase account holds 1,436,202 shares, accounting for 0.33% of the company’s total shares, ranking sixth in the company’s shareholding table of the top ten shareholders. According to relevant rules, it is not included in the list of the top ten shareholders.

The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares

□Applicable Not applicable

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.

□Applicable Not applicable

(2) Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders

□Applicable Not applicable

Zhonghong Pulin Medical Products Co., Ltd. 2025 Third Quarter Report

(3) Changes in restricted shares

Applicable □Not applicable

Unit: Share

Restrictions on sales are lifted in this period. Restrictions on sales are added in this period. Name of shareholder on the date when restrictions on sales are to be lifted. Number of shares subject to restrictions on sales at the beginning of the period. Number of shares subject to restrictions on sales at the end of the period. Reasons for restrictions on sales.

Number of shares Number of shares Period

Release restrictions on shares locked by senior executives according to the rules for shares locked by senior executives 32,572,800 0 3,257,280 35,830,080

Unlock sales restrictions in accordance with the rules for shares locked by senior executives Chen Jun 2,925 2,925 0 0

Unrestricted according to the rules of executive locked shares Yang Hao 0 0 18,750 18,750

for sale

Total 32,575,725 2,925 3,276,030 35,848,830 -- --

3. Other important matters

Applicable □Not applicable

(1) Senior managers of the company increase their shareholdings

On August 28, 2025, the company disclosed the "Announcement on the Company's Senior Management Plan to Increase Shareholdings" (Announcement No.: 2025-078), the company's general manager

Based on her confidence in the company's future development and her recognition of the company's long-term investment value, Ms. Li Yanghao plans to increase her shareholding to no less than 50,000 shares. As of this report

At the end of the period, Ms. Yang Hao had increased her holdings of 25,000 shares of the company's stock.

4. Quarterly Financial Statements

(1) Financial statements

Consolidated balance sheet

Prepared by: Zhonghong Pulin Medical Products Co., Ltd.

September 30, 2025

Unit: Yuan

Item Ending balance Beginning balance

Current assets:

Monetary funds 802,308,968.19 597,585,652.51 Settlement reserves

Loan funds

Trading financial assets 1,839,343,581.09 1,727,471,564.54 Derivative financial assets 0.00 0.00 Notes receivable 974,887.19 2,789,352.84 Accounts receivable 485,774,994.61 427,477,462.46 Accounts receivable financing 2,276,060.17 1,024,680.31 Prepayments 92,556,323.80 48,118,631.65 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 27,304,549.55 31,820,374.60

Among them: interest receivable

Zhonghong Pulin Medical Products Co., Ltd. 2025 Third Quarter Report

Dividends receivable

Buy financial assets under resale agreements

Inventory 559,322,721.39 576,387,552.98

Among them: data resources

Contract assets 0.00 Assets held for sale 0.00 Non-current assets due within one year 157,464,000.00 Other current assets 1,048,979,065.03 999,796,013.39 Total current assets 4,858,841,151.02 4,569,935,285.28 Non-current assets:

Grant loans and advances

Debt investment 14,816,112.59 14,737,886.45 Other debt investment 0.00 0.00 Long-term receivables 0.00 0.00 Long-term equity investment 33,466,374.49 32,976,617.91 Other equity instrument investment 94,469,071.54 94,016,691.95 Other non-current financial assets 145,167,709.00 139,167,709.00 Investment real estate 0.00 0.00 Fixed assets 1,779,021,598.98 1,807,880,707.08 Construction in progress 152,661,985.87 84,090,530.68 Productive biological assets 0.00 0.00 Oil and gas assets 0.00 0.00 Right-of-use assets 15,794,096.69 13,753,874.31 Intangible assets 146,319,294.61 153,560,449.39

Among them: data resources 0.00

Development expenditure 0.00 0.00

Among them: data resources 0.00

Goodwill 153,880,890.26 149,441,548.15 Long-term deferred expenses 3,011,996.85 3,624,518.87 Deferred income tax assets 58,918,586.30 58,902,258.96 Other non-current assets 195,710,428.82 108,272,718.50 Total non-current assets 2,793,238,146.00 2,660,425,511.25 Total assets 7,652,079,297.02 7,230,360,796.53 Current liabilities:

Short-term borrowings 842,421,511.72 391,527,277.31 Borrowings from the central bank

borrowing funds

Trading financial liabilities 7,688,017.08 16,082,792.40 Derivative financial liabilities 0.00 0.00 Notes payable 160,542,625.01 233,884,319.01 Accounts payable 265,295,754.17 252,653,806.79 Advance receipts 0.00 0.00 Contract liabilities 64,660,767.94 73,797,742.86 Financial assets sold under repurchase agreements

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable 63,118,271.91 69,772,426.12 Taxes payable 6,159,788.11 13,070,467.19 Other payables 13,827,372.70 28,093,052.42 Including: interest payable 0.00

Dividends payable 0.00 Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale 0.00 Non-current liabilities due within one year 106,091,462.16 148,666,729.22

Zhonghong Pulin Medical Products Co., Ltd. 2025 Third Quarter Report

Other current liabilities 2,588,264.54 8,880,799.80 Total current liabilities 1,532,393,835.34 1,236,429,413.12 Non-current liabilities:

insurance contract reserves

Long-term borrowings 561,349,847.14 330,213,742.94 Bonds payable 0.00 0.00 Among them: preference shares 0.00 0.00

Perpetual bonds 0.00 0.00 Lease liabilities 16,245,097.12 8,573,902.35 Long-term payables 0.00 0.00 Long-term employee benefits payable 0.00 0.00 Estimated liabilities 0.00 0.00 Deferred income 19,586,956.48 20,894,673.68 Deferred income tax liabilities 14,165,283.92 13,563,464.52 Other non-current liabilities 0.00 0.00 Total non-current liabilities 611,347,184.66 373,245,783.49 Total liabilities 2,143,741,020.00 1,609,675,196.61 Owners’ equity:

Share capital 428,864,959.00 390,007,800.00 Other equity instruments 0.00 0.00 Among them: preference shares 0.00 0.00

Perpetual bonds 0.00 0.00 Capital reserves 1,676,986,587.94 1,715,843,746.94 Less: treasury shares 18,985,800.89 18,985,800.89 Other comprehensive income 3,855,674.31 4,891,077.57 Special reserves 0.00 0.00 Surplus reserve 95,661,783.43 95,661,783.43 General risk reserve 0.00 0.00 Undistributed profits 3,182,330,699.80 3,286,683,752.02 Total owners’ equity attributable to the parent company 5,368,713,903.59 5,474,102,359.07 Minority shareholders’ equity 139,624,373.43 146,583,240.85 Total owners’ equity 5,508,338,277.02 5,620,685,599.92 Total liabilities and owners’ equity 7,652,079,297.02 7,230,360,796.53 Legal representative: Sang Shujun Person in charge of accounting work: Wang Wenlong Person in charge of accounting department: Zhang Yuzhu

Consolidated income statement from the beginning of the year to the end of the reporting period

Unit: Yuan

Item Amount for the current period Amount for the previous period

Total operating income 1,863,658,896.34 1,838,289,686.09 Including: operating income 1,863,658,896.34 1,838,289,686.09Interest income

Premiums earned

Fee and commission income

Total operating costs 1,889,367,380.39 1,796,999,850.39

Including: operating costs 1,667,274,550.00 1,585,741,723.51

interest expense

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Zhonghong Pulin Medical Products Co., Ltd. 2025 Third Quarter Report

Taxes and surcharges 18,636,121.65 13,940,483.58 Sales expenses 89,732,911.66 88,864,953.67

Management expenses 94,210,090.48 94,969,109.96

Research and development expenses 37,187,779.66 35,548,218.01

Financial expenses -17,674,073.06 -22,064,638.34

Including: interest expense 21,495,355.03 17,827,071.93

Interest income 39,920,495.01 52,601,631.10

Add: other income 8,851,857.94 15,854,350.20

Investment income (losses are filled in with "-"

8,761,768.44 13,338,656.88 columns)

Of which: for associates and joint ventures

corporate investment income

Measured at amortized cost

Income from derecognition of financial assets

Exchange gains (losses are filled in with "-"

column)

Net exposure hedging gain (loss calculated as

Fill in the column with "-" sign)

Gains from changes in fair value (losses calculated as

26,062,737.81 37,059,013.44 (Fill in “-”)

Credit impairment losses (losses are marked with "-"

-2,511,375.33 -1,707,513.10 fill in the column)

Asset impairment losses (losses are marked with "-"

-25,099,406.45 -42,547,150.18 fill in the column)

Asset disposal income (losses are marked with "-"

-792,071.20 -2,322.57 fill in the column)

3. Operating profit (loss is filled in with "-"

-10,434,972.84 63,284,870.37 columns)

Add: Non-operating income 2,083,617.67 171,870.99 Less: Non-operating expenses 820,260.04 1,116,922.26

4. Total profit (total loss is marked with "-"

-9,171,615.21 62,339,819.10 fill in the column)

Less: Income tax expenses 392,118.66 7,356,176.66

5. Net profit (net loss is filled in with "-"

-9,563,733.87 54,983,642.44 columns)

(1) Classification by business continuity

Net profit from continuing operations (net loss divided by

-9,563,733.87 54,983,642.44 (Fill in “-”)

Net profit from discontinued operations (net loss equal to

Fill in the column with "-" sign)

(2) Classification according to ownership ownership

Net profit attributable to shareholders of the parent company

-7,210,152.72 51,032,305.48 (Net loss is listed with "-")

Profit and loss of minority shareholders (net loss is represented by “-”

-2,353,581.15 3,951,336.96 (please fill in the list)

Net after-tax amount of other comprehensive income -1,059,948.56 499,870.01 Other comprehensive income attributable to owners of the parent company

-1,035,403.26 499,870.01 net amount after tax

(1) Others that cannot be reclassified into profit or loss

-422,655.28 -392,764.14Comprehensive income

Remeasure changes in defined benefit plans

Others that cannot be transferred to profit or loss under the equity method

Comprehensive income

Zhonghong Pulin Medical Products Co., Ltd. 2025 Third Quarter Report

Fair value of other equity instrument investments

-422,655.28 -392,764.14 change

Fair value of the company’s own credit risk

change

5.Others

(2) Other comprehensive items that will be reclassified into profit or loss

-612,747.98 892,634.15 combined income

Other comprehensive items that can be transferred to profits and losses under the equity method

combined income

Changes in fair value of other debt investments
Financial assets are reclassified into other comprehensive

Amount of combined income

Credit impairment provisions for other debt investments
Cash flow hedging reserve
Translation difference of foreign currency financial statements -612,747.98 892,634.15

7.Others

Other comprehensive income attributable to minority shareholders

-24,545.30

net of tax

Total comprehensive income -10,623,682.43 55,483,512.45

(1) Comprehensive assets attributable to owners of the parent company

-8,245,555.98 51,532,175.49Total income

(2) Comprehensive income attributable to minority shareholders

-2,378,126.45 3,951,336.96 total

8. Earnings per share:

(1) Basic earnings per share -0.0169 0.1193

(2) Diluted earnings per share -0.0169 0.1193 If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: yuan, and the net profit realized by the merged party in the previous period is: yuan.

Legal representative: Sang Shujun Person in charge of accounting work: Wang Wenlong Person in charge of accounting department: Zhang Yuzhu

Consolidated cash flow statement from the beginning of the year to the end of the reporting period

Unit: Yuan

Item Amount for the current period Amount for the previous period

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 1,755,371,866.76 1,640,649,089.77 Net increase in customer deposits and deposits from banks

Net increase in borrowing from the central bank

Net increase in borrowing funds from other financial institutions

Cash received from premiums from the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash collected from interest, fees and commissions

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

Tax refunds received 126,441,547.88 123,680,709.21 Other cash received related to operating activities 105,148,293.51 131,222,012.87 Subtotal of cash inflows from operating activities 1,986,961,708.15 1,895,551,811.85 Cash for purchasing goods and receiving services 1,518,517,607.85 1,366,441,056.65

Net increase in loans and advances to customers

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

Zhonghong Pulin Medical Products Co., Ltd. 2025 Third Quarter Report

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 299,081,573.33 291,201,009.27 Various taxes and fees paid 45,862,422.73 34,876,135.34 Other cash paid related to operating activities 214,166,479.45 189,895,126.03 Subtotal cash outflow from operating activities 2,077,628,083.36 1,882,413,327.29 Net cash flow generated from operating activities -90,666,375.21 13,138,484.56

2. Cash flow generated from investing activities:

Cash received from recovery of investment 4,819,474,084.52 2,860,269,310.85 Cash received from investment income 44,429,635.04 82,623,259.85 Disposal of fixed assets, intangible assets and other long-term assets

0.00 598,996.92 net cash amount recovered from assets

Received from disposal of subsidiaries and other business units

net cash

Other cash received related to investing activities 13,434,764.81

Subtotal of cash inflows from investing activities 4,877,338,484.37 2,943,491,567.62 Purchase and construction of fixed assets, intangible assets and other long-term assets

120,619,061.30 67,047,418.93 Cash paid for assets

Cash paid for investment 4,733,050,661.30 2,393,058,776.98 Net increase in pledged loans

Obtain payment from subsidiaries and other business units

109,878,068.45

net cash

Payment of other cash related to investing activities 13,891,871.19 5,927,056.63 Subtotal cash outflow from investing activities 4,977,439,662.24 2,466,033,252.54 Net cash flow generated from investing activities -100,101,177.87 477,458,315.08

3. Cash flow generated from financing activities:

Absorbing cash received from investments

Among them: subsidiaries absorb investment from minority shareholders

cash received

Cash received from borrowings 1,066,698,053.13 908,909,122.80 Cash received from other financing activities 0.00 1,085,409.57 Subtotal of cash inflows from financing activities 1,066,698,053.13 909,994,532.37 Cash paid to repay debts 555,559,089.40 527,840,870.02 Distribution of dividends, profits or payment of interest

121,347,246.19 215,496,640.33 cash

Including: Payments made by subsidiaries to minority shareholders

2,638,554.61 1,331,566.02 Dividends and profits

Cash payments related to other financing activities 2,335,190.13 21,600,957.58 Subtotal cash outflow from financing activities 679,241,525.72 764,938,467.93 Net cash flow generated from financing activities 387,456,527.41 145,056,064.44

4. The impact of exchange rate changes on cash and cash equivalents

8,688,992.34 -6,440,555.89 impact

Net increase in cash and cash equivalents 205,377,966.67 629,212,308.19 Plus: opening balance of cash and cash equivalents 576,952,731.32 750,755,762.20
Balance of cash and cash equivalents at the end of the period 782,330,697.99 1,379,968,070.39

(2) Adjustment of relevant items in the financial statements at the beginning of the year when the new accounting standards are first implemented starting from 2025